Optieum Biotechnologies is driving the evolution of next-generation CAR-T cell therapy with precision-engineered CAR constructs, focusing on optimizing the binding domain of CAR to enhance immune cell function for robust therapeutic efficacy, particularly in solid tumors
Optieum Biotechnologies is driving the evolution of next-generation CAR-T cell therapy with precision-engineered CAR constructs, focusing on optimizing the binding domain of CAR to enhance immune cell function for robust therapeutic efficacy, particularly in solid tumors.